Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Remarkable response of BRAFV600E-mutated metastatic pancreatic cancer to BRAF/MEK inhibition: a case report

9 Sept 2021

Abstract excerpt

Advanced pancreatic ductal adenocarcinoma (PDAC) has very limited treatment options due to few targetable mutations, and chemotherapeutic treatment is currently the mainstay of palliative therapy for PDAC patients. Somatic point mutations in the BRAF gene (mostly V600E) are present in many tumors, especially in malignant melanomas, with a mutation rate of ∼66% [1]. On the other hand, the BRAF mutation has rarely...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Melanoma and MAPK Pathways
Share to Pancreatic and Hepatic Oncology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35382161
DOI: 10.1093/gastro/goab031

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Remarkable response of BRAFV600E-mutated metastatic pancreatic cancer to BRAF/MEK inhibition: a case reportPMID 35382161Read ↗

Molecular Targeting of a BRAF Mutation in Pancreatic Ductal Adenocarcinoma: Case Report and Literature Review.Semantic proximity Read ↗

Targeted Therapy for BRAF V600E Positive Pancreatic Adenocarcinoma: Two Case Reports.Semantic proximity Read ↗

BRAF-Driven Pancreatic Cancer: Prevalence, Molecular Features, and Therapeutic Opportunities.Semantic proximity Read ↗

PD-1 blockade plus capecitabine as curative-intent treatment for tumor mutational burden-high multi-metastatic pancreatic ductal adenocarcinoma: A case reportSemantic proximity Read ↗

Epidermal growth factor receptor-activating mutation(E746_T751>VP) in pancreatic ductal adenocarcinoma responds to erlotinib, followed by epidermal growth factor receptor resistance-mediating mutation (A647T): A case report and literature review.Semantic proximity Read ↗

Metastatic Pancreatic Cancer Now in Remission: A Case Report and Literature ReviewSemantic proximity Read ↗

Early Application of Next-Generation Sequencing Identifies Pancreatic Mass as Metastasis From an EGFR-Mutated Lung Adenocarcinoma.Semantic proximity Read ↗

Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels.Semantic proximity Read ↗

First Reported Advanced Pancreatic Cancer With Hyperprogression Treated With PD-1 Blockade combined with chemotherapy: A Case Report And Literature ReviewSemantic proximity Read ↗

Successful BRAF/MEK inhibition in a patient with BRAFV600E-mutated extrapancreatic acinar cell carcinoma.Semantic proximity Read ↗

Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma.Semantic proximity Read ↗

Impact of Driver Mutations on the Evolution of Isolated Metachronous Lung Metastasis of Pancreatic Ductal adenocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.